비교리스트

 카트 문의
시장보고서
상품코드
1414722

세계 HIV 치료제 시장 : 약제 클래스별, 유통 채널별 : 기회 분석과 산업 예측(2023년-2032년)

HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 35 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HIV 치료제 시장은 2022년에는 328억 달러로 평가되었으며, 2023년부터 2032년까지 복합 연간 성장률(CAGR) 4.5%로 성장할 전망이며 2032년에는 511억 달러에 이를 것으로 추정됩니다.

인간 면역 결핍 바이러스(HIV)는 신체의 면역계를 공격하는 감염의 일종입니다. 신체를 약화시켜 모든 질병에 걸리기 쉽습니다. HIV의 치료에는 뉴클레오시드계 역전사효소 억제제(NRTI), 프로테아제 억제제(PI), 엔트리 억제제, HIV 인테그라제 사슬 전이 억제제 등의 항레트로바이러스제(HIV 치료제)가 사용됩니다.

HIV Drugs Market-IMG1

이 보고서를 사용자 정의 할 수 있습니다(별도 비용과 일정이 필요합니다.)

  • 시장 전략
  • 제품/부문별 기업 시장 세분화
  • 주요 기업의 신제품 개발/제품 매트릭스
  • 고객의 관심에 따른 추가 기업 프로파일
  • 평균 판매 가격 분석/프라이스 포인트 분석
  • 브랜드 점유율 분석
  • 크리스 크로스 부문 분석 - 시장 규모와 예측
  • 과거 시장 데이터
  • 주요 기업의 상세(소재지, 연락처, 공급자/벤더 네트워크 등을 포함한, 엑셀 형식)
  • SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 영향요인
    • 주요 투자 기회
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
      • HIV 감염자 증가
      • HIV/AIDS의 진단과 관리에 관한 인식을 높이기 위한 다양한 정부 단체에 의한 대처
      • HIV 치료제의 제네릭 의약품의 소개
    • 억제요인
      • HIV 치료제의 승인과 상업화를 위한 엄격한 규제 요건
    • 기회
      • 파이프라인 제품 증가

제4장 HIV 치료제 시장 : 약제 클래스별

  • 개요
  • 약제 클래스별 병용약
    • 약제 클래스별 배합제 HIV 치료제 브랜드별 시장
  • 뉴클레오시드 역전사효소 억제제(NRTI)
    • 뉴클레오시드계 역전사효소 억제제(NRTI) 브랜드별 HIV 치료제 시장
  • 비뉴클레오시드계 역전사효소 억제제(NNRTI)
    • 비뉴클레오시드계 역전사효소 억제제(NNRTI) HIV 치료제의 브랜드별 시장
  • 프로테아제 억제제(PI)
    • 프로테아제 억제제(PI) HIV 치료제의 브랜드별 시장
  • 엔트리 억제제
    • 엔트리 억제제의 브랜드별 HIV 치료제 시장
  • HIV 인테그라아제 사슬 전이 억제제
    • HIV 인테그라제 사슬 이행 억제제 HIV 치료제의 브랜드별 시장
  • 기타

제5장 HIV 치료제 시장 : 유통 채널별

  • 개요
  • 병원 약국
  • 약국 및 소매 약국
  • 온라인 약국

제6장 HIV 치료제 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타
  • 아시아태평양
    • 일본
    • 중국
    • 호주
    • 인도
    • 한국
    • 기타
  • 라틴아메리카 및 중동 및 아프리카
    • 브라질
    • 사우디아라비아
    • 남아프리카
    • 기타

제7장 경쟁 구도

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝(2022년)

제8장 기업 프로파일

  • AbbVie Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Bristol-Myers Squibb Company
BJH 24.02.06

According to a new report published by Allied Market Research, titled, "HIV Drugs Market," The hiv drugs market was valued at $32.8 billion in 2022, and is estimated to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) is a type of infection that attacks the immune system of the body. It weakens the body and makes it easier to get sick with any diseases. The antiretroviral drugs (HIV drugs) such as nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others are used for the treatment of HIV.

HIV Drugs Market - IMG1

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Go To Market Strategy
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis / Price Point Analysis
  • Brands Share Analysis
  • Criss-cross segment analysis- market size and forecast
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Medication Class

  • Multi-Class Combination Drugs
    • Brand
    • Atripla
    • Complera
    • Prezcobix
    • Stribild
    • Genvoya
    • Odefsey
    • Symtuza
    • Triumeq
    • Descovy
    • Dovato
    • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Brand
    • Emtriva
    • Epivir
    • Epzicom/Kivexa
    • Truvada
    • Biktarvy
    • Others
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Brand
    • Edurant
    • Others
  • Protease Inhibitors (PIs)
    • Brand
    • Aptivus
    • Kaletra
    • Lexiva/ Telzir
    • Norvir
    • Viracept
    • Others
  • Entry Inhibitors
    • Brand
    • Selzentry
    • Fuzeon
    • Rukobia
  • HIV Integrase Strand Transfer Inhibitors
    • Brand
    • Isentress/Isentress HD
    • Tivicay
    • Apretude
    • Juluca
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drugs stores and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Merck & Co., Inc.
    • Cipla Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in cases of HIV
      • 3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
      • 3.4.1.3. Introduction of generic drugs for HIV
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Increasing number of products in the pipeline

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Multi-Class Combination Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand
  • 4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand
  • 4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
    • 4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand
  • 4.5. Protease Inhibitors (PIs)
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
    • 4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand
  • 4.6. Entry Inhibitors
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
    • 4.6.4. Entry Inhibitors HIV Drugs Market by Brand
  • 4.7. HIV Integrase Strand Transfer Inhibitors
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
    • 4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital Pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drugs stores and retail pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online pharmacies
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HIV DRUGS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Medication Class
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Medication Class
      • 6.2.4.1.2. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Medication Class
      • 6.2.4.2.2. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Medication Class
      • 6.2.4.3.2. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Medication Class
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Medication Class
      • 6.3.4.1.2. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Medication Class
      • 6.3.4.2.2. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Medication Class
      • 6.3.4.3.2. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Medication Class
      • 6.3.4.4.2. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Medication Class
      • 6.3.4.5.2. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Medication Class
      • 6.3.4.6.2. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Medication Class
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Medication Class
      • 6.4.4.1.2. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Medication Class
      • 6.4.4.2.2. Market size and forecast, by Distribution Channel
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Market size and forecast, by Medication Class
      • 6.4.4.3.2. Market size and forecast, by Distribution Channel
      • 6.4.4.4. India
      • 6.4.4.4.1. Market size and forecast, by Medication Class
      • 6.4.4.4.2. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Medication Class
      • 6.4.4.5.2. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Medication Class
      • 6.4.4.6.2. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Medication Class
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Medication Class
      • 6.5.4.1.2. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Medication Class
      • 6.5.4.2.2. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Medication Class
      • 6.5.4.3.2. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Medication Class
      • 6.5.4.4.2. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. AbbVie Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Merck & Co., Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Boehringer Ingelheim International GmbH
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Gilead Sciences, Inc.
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. GlaxoSmithKline plc
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Johnson & Johnson
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. F. Hoffmann-La Roche Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
  • 8.8. Teva Pharmaceutical Industries Ltd.
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Cipla Ltd.
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제